TRANS GENIC GROUP INC. Logo

TRANS GENIC GROUP INC.

Biotech firm offering drug discovery support and investment/consulting services.

2342 | T

Overview

Corporate Details

ISIN(s):
JP3635720000
LEI:
Country:
Japan
Address:
福岡市中央区天神二丁目3番36号

Description

TRANS GENIC GROUP INC. is a biotechnology company that operates through two main business segments: Drug Discovery Support and Investment & Consulting. The Drug Discovery Support division provides comprehensive services across the entire drug development pipeline, from basic research to non-clinical and clinical trials. Core services include the contract production of genetically modified animals, particularly mice, using genome editing technologies like CRISPR/Cas9. The company also specializes in contract antibody production, glycosylation analysis, and the supply of model mice. The Investment & Consulting segment focuses on M&A, business succession, and providing advisory and support services for business revitalization.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-13 02:36
確認書
Japanese 8.2 KB
2025-11-13 02:33
半期報告書-第28期(2025/04/01-2026/03/31)
Japanese 189.2 KB
2025-08-01 09:45
訂正確認書
Japanese 8.2 KB
2025-08-01 09:44
訂正有価証券報告書-第27期(2024/04/01-2025/03/31)
Japanese 667.3 KB
2025-07-02 05:53
訂正臨時報告書
Japanese 24.4 KB
2025-07-01 10:02
臨時報告書
Japanese 24.4 KB
2025-06-30 09:38
確認書
Japanese 8.6 KB
2025-06-30 09:37
内部統制報告書-第27期(2024/04/01-2025/03/31)
Japanese 23.7 KB
2025-06-30 09:34
有価証券報告書-第27期(2024/04/01-2025/03/31)
Japanese 1.1 MB
2025-06-13 10:13
臨時報告書
Japanese 21.2 KB
2025-04-23 09:55
臨時報告書
Japanese 20.1 KB
2024-11-13 02:42
確認書
Japanese 8.5 KB
2024-11-13 02:41
半期報告書-第27期(2024/04/01-2025/03/31)
Japanese 191.9 KB
2024-06-24 08:30
臨時報告書
Japanese 19.8 KB
2024-06-21 07:03
有価証券報告書-第26期(2023/04/01-2024/03/31)
Japanese 1.0 MB

Automate Your Workflow. Get a real-time feed of all TRANS GENIC GROUP INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for TRANS GENIC GROUP INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for TRANS GENIC GROUP INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Avalo Therapeutics, Inc. Logo
Clinical-stage biotech developing treatments for immune-mediated inflammatory diseases.
United States of America
AVTX
Azenta, Inc. Logo
Offers sample management, storage, and multiomics solutions for life sciences.
United States of America
AZTA
BenevolentAI Logo
Applies artificial intelligence to accelerate drug discovery and development.
United Kingdom
BAI
bioAffinity Technologies, Inc. Logo
Develops noninvasive diagnostics and targeted therapeutics for cancer.
United States of America
BIAF
BioArctic Logo
Biopharmaceutical firm developing antibody therapies for neurodegenerative diseases.
Sweden
BIOA
BioInfra Co.,Ltd. Logo
Develops multi-biomarker blood tests for early cancer screening and gene treatments.
South Korea
199730
BioInfra Life Science Inc. Logo
Develops multi-biomarker blood tests for early cancer screening and gene treatments.
South Korea
266470
BioNexus Gene Lab Corp Logo
Develops gene-based diagnostics for early detection of disease susceptibility.
United States of America
BGLC
Biophytis S.A. Logo
Clinical-stage biotech developing therapeutics for age-related degenerative diseases.
France
ALBPS
BioRestorative Therapies, Inc. Logo
Develops adult stem cell therapies for degenerative disc and metabolic disorders.
United States of America
BRTX

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.